Short Interest in Avalo Therapeutics, Inc. (NASDAQ:AVTX) Decreases By 46.9%

Avalo Therapeutics, Inc. (NASDAQ:AVTX) was the target of a significant decline in short interest in November. As of November 30th, there was short interest totalling 5,200 shares, a decline of 46.9% from the November 15th total of 9,800 shares. Currently, 0.1% of the shares of the company are sold short. Based on an average trading volume of 45,100 shares, the short-interest ratio is presently 0.1 days.

Institutional Investors Weigh In On Avalo Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in AVTX. RA Capital Management L.P. purchased a new position in Avalo Therapeutics in the 3rd quarter valued at about $9,186,000. Ikarian Capital LLC grew its position in shares of Avalo Therapeutics by 1,673.0% in the third quarter. Ikarian Capital LLC now owns 970,359 shares of the company’s stock valued at $9,218,000 after purchasing an additional 915,629 shares during the period. Logos Global Management LP acquired a new position in Avalo Therapeutics in the second quarter valued at $6,722,000. Finally, Affinity Asset Advisors LLC lifted its position in Avalo Therapeutics by 350.0% during the second quarter. Affinity Asset Advisors LLC now owns 45,000 shares of the company’s stock worth $561,000 after buying an additional 35,000 shares during the period. 87.06% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright initiated coverage on Avalo Therapeutics in a research note on Thursday, October 24th. They issued a “neutral” rating on the stock.

Avalo Therapeutics Stock Performance

Shares of AVTX traded up $0.12 on Friday, reaching $9.23. The stock had a trading volume of 189,176 shares, compared to its average volume of 203,906. Avalo Therapeutics has a twelve month low of $3.95 and a twelve month high of $34.46. The firm has a 50-day moving average of $11.17 and a 200 day moving average of $10.84.

Avalo Therapeutics Company Profile

Avalo Therapeutics, Inc, a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. The company's drug candidates include AVTX-009, an Anti-IL-1ß monoclonal antibody which is under Phase I targeting inflammatory diseases; and AVTX-008, a fully human B and T lymphocyte attenuator agonist fusion protein for the treatment of immune dysregulation disorders.